Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
BACKGROUND: This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH).
METHODS: The retrospective study conducted from April 2019 to November 2022, included PLWH with < 50 copies/mL of HIV-RNA prior to recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated.
RESULTS: 690 PLWH were included, 358 in the D/L and 332 in the B/F/T, and a median follow-up of 728 and 1013 days, respectively. The discontinuation proportions were 8.7% (31 participants, incidence rate of 4.44 per 100 PYFU in the D/L group and 15.3% (51 participants, incidence rate of 6.25 per 100 PYFU) in the B/F/T group. The adjusted hazard ratio for B/F/T discontinuation compared to D/L was 1.20 (95% CI: 0.71;2.0; p = 0.494). Virologic failure (VL > 200 copies/mL in two consecutive measurements) occurred in 1.1% and 0.9% of patients in the D/L and B/F/T groups, respectively. Notably, one patient in D/L group with severe non-adherence and virologic failure developed resistance mutations.
CONCLUSIONS: Switching to either B/T/F or D/L treatment for PLWH was effective and well tolerated in this real-world study. Treatment discontinuation rates did not significantly differ between the two regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
HIV research & clinical practice - 24(2023), 1 vom: 20. Juli, Seite 2239564 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Knobel, Hernando [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 28.07.2023 Date Revised 17.08.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM359943322 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359943322 | ||
| 003 | DE-627 | ||
| 005 | 20231226081942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359943322 | ||
| 035 | |a (NLM)37494280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Knobel, Hernando |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2023 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH) | ||
| 520 | |a METHODS: The retrospective study conducted from April 2019 to November 2022, included PLWH with < 50 copies/mL of HIV-RNA prior to recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated | ||
| 520 | |a RESULTS: 690 PLWH were included, 358 in the D/L and 332 in the B/F/T, and a median follow-up of 728 and 1013 days, respectively. The discontinuation proportions were 8.7% (31 participants, incidence rate of 4.44 per 100 PYFU in the D/L group and 15.3% (51 participants, incidence rate of 6.25 per 100 PYFU) in the B/F/T group. The adjusted hazard ratio for B/F/T discontinuation compared to D/L was 1.20 (95% CI: 0.71;2.0; p = 0.494). Virologic failure (VL > 200 copies/mL in two consecutive measurements) occurred in 1.1% and 0.9% of patients in the D/L and B/F/T groups, respectively. Notably, one patient in D/L group with severe non-adherence and virologic failure developed resistance mutations | ||
| 520 | |a CONCLUSIONS: Switching to either B/T/F or D/L treatment for PLWH was effective and well tolerated in this real-world study. Treatment discontinuation rates did not significantly differ between the two regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bictegravir/Emtricitabine/Tenofovir alafenamide | |
| 650 | 4 | |a Dolutegravir/lamivudine | |
| 650 | 4 | |a Switching antiretroviral therapy | |
| 650 | 4 | |a optimizing antiretroviral therapy | |
| 650 | 4 | |a real-world data | |
| 650 | 7 | |a tenofovir alafenamide |2 NLM | |
| 650 | 7 | |a EL9943AG5J |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a dolutegravir |2 NLM | |
| 650 | 7 | |a DKO1W9H7M1 |2 NLM | |
| 650 | 7 | |a bictegravir |2 NLM | |
| 650 | 7 | |a 8GB79LOJ07 |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 4 or More Rings |2 NLM | |
| 700 | 1 | |a Cañas-Ruano, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Guelar, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Knobel, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Villar-García, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a González-Mena, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Canepa, Ceclia |e verfasserin |4 aut | |
| 700 | 1 | |a Arrieta-Aldea, Itziar |e verfasserin |4 aut | |
| 700 | 1 | |a Marcos, Augustin |e verfasserin |4 aut | |
| 700 | 1 | |a Abalat-Torrres, Agustí |e verfasserin |4 aut | |
| 700 | 1 | |a Güerri-Fernández, Roberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV research & clinical practice |d 2019 |g 24(2023), 1 vom: 20. Juli, Seite 2239564 |w (DE-627)NLM299161706 |x 2578-7470 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:20 |g month:07 |g pages:2239564 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 20 |c 07 |h 2239564 | ||